Celecoxib ameliorates non-alcoholic steatohepatitis in type 2 diabetic rats via suppression of the non-canonical Wnt signaling pathway expression

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Tian, Feng ^a   Zhang, Ya Jie ^a   Li, Yu ^b   Xie, Ying ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Department of Neurology   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CELECOXIB; CYCLOOXYGENASE 2; INSULIN; STREPTOZOCIN; STRESS ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR RELA; WNT PROTEIN; WNT5A PROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARBOHYDRATE DIET; CONTROLLED STUDY; HEPATITIS; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIVER INJURY; LIVER WEIGHT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; WESTERN BLOTTING; WNT SIGNALING PATHWAY;

ANIMALS; BIOLOGICAL MARKERS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DIABETES MELLITUS, TYPE 2; DIET; FATTY LIVER; LIVER; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 8; ORGAN SIZE; PYRAZOLES; RATS; SULFONAMIDES; TRANSCRIPTION FACTOR RELA; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84896747760     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083819     Document Type: Article

References (37)

1. Musso G, Gambino R, Cassader M (2010) Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 11:430-45.
2. Clark JM (2006) The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 40 Suppl 1:S5-10.
3. Rivera CA (2008) Risk factors and mechanisms of non-alcoholic steatohepatitis. Pathophysiology 15:109-14.
4. Lo L, McLennan SV, Williams PF, Bonner J, Chowdhury S, et al. (2011) Diabetes is a progression factor for hepatic fibrosis in high fat fed mouse obesity model of non-alcoholicsteatohepatitis. J Hepatol 55:435-44.
5. Braunersreuther V, Viviani GL, Mach F, Montecucco F (2012) Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol 18:727-35.
6. Yu J, Ip E, Dela Peña A, Hou JY, Sesha J, et al. (2006) COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator. Hepatology 43:826-36.
7. Leclercq IA, Farrell GC, Sempoux C, dela Peña A, Horsmans Y (2004) Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol 41:926-934. (Pubitemid 39575659)
8. Hsieh PS, Jin JS, Chiang CF, Chan PC, Chen CH, et al. (2009) COX-2-mediated Inflammation in Fat Is Crucial for Obesity-linked Insulin Resistance and Fatty Liver. Obesity(Silver Spring) 17:1150-7.
9. Wu HT, Chen W, Cheng KC, Yeh CH, Shen KH, et al. (2010) Indomethacin activates peroxisome proliferator-activated receptor γ to improve insulin resistance in cotton pelletgranuloma model. Horm Metab Res 42:775-80.
10. Vaish V, Tanwar L, Sanyal SN (2010) The role of NF-κB and PPARγ in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors. Tumour Biol 31:427-36.
11. Kikuchi A, Yamamoto H, Sato A, Matsumoto S (2012) Wnt5a: its signaling, functions and implication in diseases. Acta Physiol (Oxf) 204:17-33.
12. Behari J, Yeh TH, Krauland L, Otruba W, Cieply B, et al. (2010) Liver-specific beta-catenin knockout mice exhibit defective bile acid and cholesterol homeostasis and increased susceptibility to diet-induced steatohepatitis. Am J Pathol 176:744-53.
13. Ouchi N, Higuchi A, Ohashi K, Oshima Y, Gokce N, et al. (2010) Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science 329:454-7.
14. Katoh M, Katoh M (2009) Transcriptional mechanisms of WNT5A based on NF-kB, Hedgehog, TGFb, and Notch signaling cascades. Int J Mol Med 23:763-9.
15. Fukuda T, Chen L, Endo T, Tang L, Lu D, et al.(2008) Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A 105:3047-52. (Pubitemid 351723665)
16. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, et al.(2011) Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53:810-20.
17. Sheth SG, Gordon FD, Chopra S (1997) Nonalcoholic steatohepatitis. Ann Intern Med 126:137-145. (Pubitemid 27058588)
18. Chatrath H, Vuppalanchi R, Chalasani N (2012) Dyslipidemia in patients with Nonalcoholic fatty liver disease. Semin Liver Dis 32:22-9.
19. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, et al. (2001) Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293:1673-7. (Pubitemid 32807849)
20. Dela Peña A, Leclercq I, Field J, George J, Jones B, et al. (2005) NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 129:1663-74. (Pubitemid 41597405)
21. Boden G, She P, Mozzoli M, Cheung P, Gumireddy K, et al. (2005) Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factorkappaB pathway in rat liver. Diabetes 54: 3458-65. (Pubitemid 43334336)
22. Vandoros GP, Konstantinopoulos PA, Sotiropoulou-Bonikou G, Kominea A, Papachristou GI, et al. (2006) PPAR-gamma is expressed and NF-κ B pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. J Cancer Res Clin Oncol 132:76-84. (Pubitemid 41752048)
23. Benitah SA Valerón PF, Lacal JC (2003) ROCK and nuclear factor-κ Bdependent activation of cyclooxygenase-2 by Rho GTPases:effects on tumor growth and therapeutic consequences. Mol Biol Cell 14:3041-54. (Pubitemid 36871540)
24. Kawai M, Mushiake S, Bessho K, Murakami M, Namba N, et al. (2007) Wnt/Lrp/beta-catenin signaling suppresses adipogenesis by inhibiting mutual activation of PPARgamma and C/EBPalpha. Biochem Biophys Res Commun 363:276-282. (Pubitemid 47484327)
25. Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, et al. (2000) Inhibition of adipogenesis by Wnt signaling. Science 289:950-3. (Pubitemid 30659947)
26. Gustafson B, Smith U (2006) Cytokines promote Wnt signaling and inflammation and impair the normal differentiation and lipid accumulation in 3T3-L1 preadipocytes. J Biol Chem 281:9507-16. (Pubitemid 43864668)
27. Abiola M, Favier M, Christodoulou-Vafeiadou E, Pichard AL, Martelly I, et al. (2009) Activation of Wnt/beta-catenin signaling increases insulin sensitivity through a reciprocal regulation of Wnt10b and SREBP-1c in skeletal muscle cells. PLoS One 4:e8509.
28. Schulte DM, Müller N, Neumann K, Oberhäuser F, Faust M, et al. (2012) Proinflammatory wnt5a and anti-inflammatory sFRP5 are differentially regulated by nutritionalfactors in obese human subjects. PLoS One 7: e32437.
29. Lehwald N, Tao GZ, Jang KY, Papandreou I, Liu B, et al. (2012) β-Catenin Regulates Hepatic Mitochondrial Function and Energy Balance in Livers of Mice. Gastroenterology 143:754-64.
30. Morris EM, Rector RS, Thyfault JP, Ibdah JA (2011) Mitochondria and redox signaling in steatohepatitis. Antioxid Redox Signal 15:485-504.
31. Veeman MT, Axelrod JD, Moon RT (2003) A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. Dev Cell 5:367-77. (Pubitemid 37107667)
32. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, et al. (2004) Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279:32345-32353. (Pubitemid 39014687)
33. Lu S, Archer MC (2007) Celecoxib decreases fatty acid synthase expression via down-regulation of c-Jun N-terminal kinase-1. Exp Biol Med (Maywood) 232:643-53. (Pubitemid 46683390)
34. Nuñez F, Bravo S, Cruzat F, Montecino M, De Ferrari GV (2011) Wnt/βcatenin signaling enhances cyclooxygenase-2(COX2) transcriptional activity in gastric cancer cells. PLoS One 6:e18562.
35. Buchanan FG, DuBois RN (2006) Connecting COX-2 and Wnt in cancer. Cancer Cell 9:6-8. (Pubitemid 43069505)
36. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS (2005) Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-betacatenin signaling axis. Science 310:1504-10. (Pubitemid 41746348)
37. Tuynman JB, Vermeulen L, Boon EM, Kemper K, Zwinderman AH, et al. (2008) Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res 68:1213-20. (Pubitemid 351272241)